Document is current
Any future updates will be listed below
-
Authors
Cui, Lian https://orcid.org/0000-0003-0997-6424
Lu, Hengli
Cai, Jiangluyi
Li, Ying https://orcid.org/0000-0002-4041-2646
Chen, Zeyu
Zhang, Yiwei https://orcid.org/0000-0002-2329-588X
Li, Bingjie https://orcid.org/0000-0002-4871-7444
Wang, Yuanyuan
Yang, Nan
Yao, Lingling
Ma, Rui
Wang, Xin
Yu, Yingyuan
Huang, Dawei https://orcid.org/0000-0003-0732-1467
Zhu, Peiyao
Mei, Hao
Chen, Qianyu
Zhuang, Yu
Gao, Yunlu
Yu, Ning
Zhang, Lingjuan https://orcid.org/0000-0001-6937-4578
Guo, Chunyuan https://orcid.org/0000-0001-6769-1713
Xiang, Huijing https://orcid.org/0000-0002-7465-3392
Shi, Yuling https://orcid.org/0000-0002-1273-7881
- License Information
-
More Information
Article History
Received: 1 July 2024
Accepted: 27 April 2026
First Online: 13 May 2026
Competing interests
: L.C., H.L., J.C., Z.C., Y.W., Nan.Y., L.Y., C.G., and Y.S. are listed as inventors on Chinese patent applications (LYI23389 and LYI23430) filed by Shanghai Skin Disease Hospital, which cover the use of Mo 90 Ce 10 or its combination with TD-1 and MTX for the treatment of skin inflammation. The remaining authors declare no competing interests.
